All
End-of-Life Care Is Suboptimal in Elderly Patients With AML
August 25th 2017End-of-life care is of particular concern for elderly patients with AML because prognosis is poor and has not changed in several decades. Median survival for patients 65 or older is roughly two months and drops to as low as one month for patients over 85 years.
XPO1 Inhibitor Offers Novel Mechanism for Treating Penta-Refractory Myeloma
August 23rd 2017Selinexor (KPT-330), a small-molecule inhibitor with a novel mechanism of action, is being investigated in patients with multiple myeloma (MM) who have become refractory to the many new options that have been introduced in recent years for patients with the malignancy.